Submena, 100 micrograms, sublingual tablets
Submena, 200 micrograms, sublingual tablets
Submena, 400 micrograms, sublingual tablets
Submena, 800 micrograms, sublingual tablets
Fentanyl
You should carefully read the contents of the leaflet before taking the medicine, as it contains
important information for the patient.
Submena is a medicine intended for adults who already regularly take strong painkillers (opioids)
to control chronic cancer pain, but also require treatment for breakthrough pain.If you are not sure if this applies to you, you should consult your doctor.
Breakthrough pain is additional, sudden pain that occurs despite the regular use of opioid painkillers by the patient.
The active substance in Submena is fentanyl. Fentanyl belongs to a group of strong painkillers called opioids.
The medicine should be kept in a safe place, out of the reach of unauthorized persons (more information can be found in section 5 "How to store Submena").
Before starting treatment with Submena, you should discuss with your doctor if you have or have recently had any of the following symptoms, as the doctor will need to take them into account when adjusting the dose:
While taking Submena, you should inform your doctor, including your dentist, that you are taking this medicine if:
Long-term use and tolerance
This medicine contains fentanyl, which is an opioid medicine. Long-term use of opioid painkillers can cause the medicine to become less effective (the body gets used to it, known as tolerance to the medicine). You may also become more sensitive to pain while taking Submena. This is called hyperalgesia. Increasing the dose of Submena may help to further reduce pain for a while, but it can also be harmful. If you find that the medicine is becoming less effective, you should consult your doctor. The doctor will decide whether it is better to increase the dose or gradually decrease the dose of Submena.
Dependence and addiction
This medicine contains fentanyl, which is an opioid. It can cause dependence and/or addiction.
Long-term use of Submena can also lead to dependence, abuse, and addiction, which can result in life-threatening overdose. The risk of these side effects may increase with increasing dose and longer treatment duration.
Dependence can cause you to lose control over the amount of medicine you take or how often you take it. You may feel compelled to take the medicine, even if it does not help to relieve pain. The risk of dependence and addiction varies from person to person. The risk of dependence may be higher if:
If you experience any of the following symptoms while taking Submena, it may indicate dependence
If you notice any of these symptoms, you should consult your doctor to discuss the best treatment method, including when and how to safely stop the medicine.
Respiratory depression during sleep
Submena can cause respiratory depression during sleep, such as sleep apnea (pauses in breathing during sleep) and hypoxemia (low oxygen level in the blood). Symptoms can include pauses in breathing during sleep, nighttime awakenings due to shortness of breath, difficulty staying asleep, or excessive daytime sleepiness. If you or someone else notices such symptoms, you should contact your doctor. The doctor may consider reducing the dose.
You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take (other than your regular opioid painkiller).
Some medicines can enhance or reduce the effect of Submena. Therefore, when starting, changing the dose, or stopping the following medicines, you should inform your doctor, as it may be necessary to adjust the dose of Submena:
Submena can enhance the effect of medicines that cause drowsiness (sedatives):
Taking Submena with sedatives (such as benzodiazepines) can increase the risk of drowsiness, breathing difficulties (respiratory depression), sleepiness, and can be life-threatening. Therefore, taking Submena with sedatives should only be considered when other treatment options are not possible.
However, if your doctor prescribes Submena with a sedative, the dose and treatment duration should be limited.
You should tell your doctor about all sedatives you are taking and strictly follow the doctor's instructions regarding dosing. It may be helpful to inform friends or family members to watch for the signs and symptoms listed above. If such symptoms occur, you should contact your doctor.
The risk of certain other side effects may increase if you take certain antidepressant or antipsychotic medicines. Submena can interact with these medicines, and you may experience changes in mental state (e.g. agitation, hallucinations, sleepiness) and other effects, such as body temperature above 38°C, increased heart rate, unstable blood pressure, exaggerated reflexes, muscle stiffness, and lack of coordination and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhea).
In some people, Submena can cause drowsiness. You should not drink alcohol without consulting your doctor, as alcohol can cause increased drowsiness.
You should not drink grapefruit juice while taking Submena, as it may increase the risk of side effects.
Submena should not be used during pregnancy, unless your doctor advises otherwise.
Fentanyl can pass into breast milk and cause side effects in breastfed babies. You should not start breastfeeding until at least 5 days after the last dose of Submena.
Submena can impair your mental and/or physical ability to perform potentially hazardous activities, such as driving or operating machinery.
If you experience dizziness, drowsiness, or blurred vision while taking Submena, you should not drive or operate machinery.
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means that it is essentially "sodium-free".
Before taking Submena for the first time, your doctor will explain how to take it to effectively treat breakthrough pain.
Before starting treatment and regularly during treatment, your doctor will discuss your expectations regarding Submena, when and how long to take it, when to contact the doctor, and when to stop the medicine (see also section 2).
This medicine should always be taken exactly as prescribed by your doctor or pharmacist. If you are unsure, you should ask your doctor or pharmacist.
This medicine should only be used as directed by your doctor. It should not be used by other people, as it may pose a serious risk to their health, especially in children.
Submena is different from other medicines you may have taken for breakthrough pain. You should always take the dose of Submena prescribed by your doctor– it may be different from the dose you took for other medicines for breakthrough pain.
Starting treatment – finding the right dose for you
To work effectively, your doctor will need to determine the right dose of Submena for you to treat breakthrough pain. Submena is available in different strengths. You may need to try different strengths of Submena over several episodes of breakthrough pain to find the right dose. Working with you, your doctor will help you find the right dose.
If one dose does not provide enough pain relief, your doctor may prescribe an additional dose to treat the episode of breakthrough pain.
You should not take a second dose without your doctor's advice, as this may lead to overdose.
Sometimes your doctor may prescribe a dose that consists of more than one tablet at the same time. This should only be done on the advice of your doctor.
You should wait at least 2 hours after taking the last dose of Submena before taking another dose for breakthrough pain.
Continuing treatment – after finding the right dose for you
After you and your doctor have determined the dose that controls your breakthrough pain, you should not take it more than four times a day. The dose of Submena may consist of more than one tablet.
You should wait at least 2 hours after taking the last dose of Submena before taking another dose for breakthrough pain.
If the chosen dose of Submena is not enough to relieve breakthrough pain, you should contact your doctor, who will decide whether the dose should be changed.
You should not change the dose of Submena without your doctor's explicit advice.
Taking the medicine
Submena should be taken sublingually, which means that the tablet should be placed under the tongue, where it dissolves quickly, allowing the fentanyl to be absorbed through the mucous membrane of the mouth. After absorption, the fentanyl starts to work to relieve pain.
If you experience such symptoms, you should seek medical help immediately.
Overdose can also cause brain disorders known as toxic leukoencephalopathy.
If you think someone has accidentally taken Submena, you should seek medical help immediately.
You should stop taking Submena when breakthrough pain no longer occurs. However, you should continue to take your regular opioid painkiller to treat chronic cancer pain, as directed by your doctor. After stopping Submena, you may experience withdrawal symptoms similar to possible side effects of Submena. If you experience withdrawal symptoms or are concerned about pain relief, you should contact your doctor. The doctor will assess whether you need a medicine to reduce or eliminate withdrawal symptoms.
If you have any further questions about taking this medicine, you should ask your doctor or pharmacist.
Like all medicines, Submena can cause side effects, although not everybody gets them.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Frequency not known (cannot be estimated from the available data):
Prolonged use of fentanyl during pregnancy may cause withdrawal symptoms in the newborn, which can be life-threatening (see section 2).
If you experience any side effects, including any not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the
Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products,
Jerozolimskie Avenue 181C,
02-222 Warsaw,
phone: +48 22 49 21 301,
fax: +48 22 49 21 309,
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects can help to gather more information on the safety of this medicine.
Do not use this medicine after the expiry date stated on the packaging after EXP.
The expiry date refers to the last day of the month stated.
Store in the original packaging to protect from moisture.
There are no special storage temperature requirements for the medicinal product.
The medicine should be kept in a safe place, out of the reach of unauthorized persons.
This medicine can cause serious harm, even death, to individuals who take it accidentally or intentionally, if it has not been prescribed for them by a doctor.
It is recommended to store Submena in a secure, closed place.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance is fentanyl. One sublingual tablet contains:
157 micrograms of micronized fentanyl citrate, equivalent to 100 micrograms of fentanyl (Fentanyl).
314 micrograms of micronized fentanyl citrate, equivalent to 200 micrograms of fentanyl (Fentanyl).
628 micrograms of micronized fentanyl citrate, equivalent to 400 micrograms of fentanyl (Fentanyl).
1257 micrograms of micronized fentanyl citrate, equivalent to 800 micrograms of fentanyl (Fentanyl).
Excipients: mannitol, microcrystalline cellulose, anhydrous colloidal silica, sodium croscarmellose, magnesium stearate.
Submena is a small white sublingual tablet intended for placement under the tongue. It is available in different strengths and shapes. Your doctor will prescribe the strength (shape) and number of tablets suitable for you.
Submena, 100 micrograms, sublingual tablet is a white, round tablet with a diameter of 6 mm.
Submena, 200 micrograms, sublingual tablet is a white, oval tablet with dimensions of 7 x 5 mm.
Submena, 400 micrograms, sublingual tablet is a white, diamond-shaped tablet with dimensions of 9 x 7 mm.
Submena, 800 micrograms, sublingual tablet is a white, capsule-shaped tablet with dimensions of 10 x 6 mm.
Submena is available in single-dose blisters with a child-resistant closure, containing 30 x 1 tablet.
G.L. Pharma GmbH
Schlossplatz 1
8502 Lannach
Austria
Prasfarma S.L.
Kern Pharma S.L.
G.L. Pharma GmbH
Schlossplatz 1
8502 Lannach
Austria
To obtain more detailed information about this medicine, you should contact the local representative of the marketing authorization holder:
G.L. PHARMA POLAND Sp. z o.o.
Al. Jana Pawła II 61/313
01-031 Warsaw, Poland
Phone: 022/ 636 52 23; 636 53 02
biuro@gl-pharma.pl
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Netherlands Submena
Italy Sublifen
Czech Republic Menasu
Slovakia Submena
Bulgaria Sublifen
Poland Submena
Sweden Submena
Denmark Sublifen
Austria Submena
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.